No plan to delist Ranbaxy despite speculation over Sun interest
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo has clarified that it has no plan to delist its troubled Indian subsidiary Ranbaxy Laboratories, amid speculation on local bourses that people close to the top executive of one leading Indian firm may be acquiring shares in anticipation of a potential offer.